Abeer M Shaaban

List of Publications by Year in Descending Order

109 papers	1,927 citations	24 h-index	41 g-index
123 ext. papers	2,315 ext. citations	5.4 avg, IF	4.62 L-index

#	Paper	IF	Citations
109	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study).. *BMJ Open*, **2022**, 12, e058050	3	0
108	Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions.. *Cell Reports*, **2022**, 38, 110320	10.6	1
107	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.. *Breast*, **2022**, 61, 145-155	3.6	0
106	Abstract P3-12-36: The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project. *Cancer Research*, **2022**, 82, P3-12-36-P3-12-36	10.1	
105	Abstract P1-22-01: Predictors of inaccurate pre-operative size assessment of screen detected DCIS and impact on recurrence rates. *Cancer Research*, **2022**, 82, P1-22-01-P1-22-01	10.1	
104	Abstract P1-22-06: A longitudinal cohort study of outcomes in 311 women with unresected ductal carcinoma in situ detected through the English breast screening programme. *Cancer Research*, **2022**, 82, P1-22-06-P1-22-06	10.1	
103	Abstract P2-13-08: Combined peri-operative lapatinib and trastuzumab in early HER2-positive breast cancer - Long term results of the randomized UK EPHOS-B trial. *Cancer Research*, **2022**, 82, P2-13-08-P2-13-08	10.1	
102	Diagnostic pitfalls in needle core biopsy of the breast. *Diagnostic Histopathology*, **2022**, 28, 156-160	0.7	1
101	Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. *British Journal of Cancer*, **2021**,	8.7	5
100	Elucidating the chemical and structural composition of breast cancer using Raman micro-spectroscopy. *EXCLI Journal*, **2021**, 20, 1118-1132	2.4	1
99	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio 2.0, HER2 copy number . *British Journal of Cancer*, **2021**, 124, 1836-1842	8.7	2
98	Why is LCIS Important Pathological Review. *Current Breast Cancer Reports*, **2021**, 13, 132-140	0.8	2
97	Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice. *Histopathology*, **2021**, 79, 47-56	7.3	3
96	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. *British Journal of Cancer*, **2021**, 124, 1009-1017	8.7	12
95	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. *Modern Pathology*, **2021**, 34, 1271-1281	6.8	12
94	Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation. *Journal of Pathology: Clinical Research*, **2021**, 7, 191-202	5.3	2
93	Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project". *British Journal of Cancer*, **2021**, 124, 1463-1464	8.7	1

92	Histopathology during the COVID-19 pandemic: resilience through adaptation and innovation. *Diagnostic Histopathology*, **2021**, 27, 108-115	0.7	1
91	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. *Modern Pathology*, **2021**, 34, 2130-2140	9.8	2
90	Male breast cancer: an update. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1	5.1	1
89	Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. *Lancet Oncology, The*, **2021**, 22, e435-e445	21.7	1
88	The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. *Histopathology*, **2020**, 76, 942-949	7.3	4
87	Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 945-955	6.1	7
86	Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement. *British Journal of Cancer*, **2020**, 122, 473-482	8.7	16
85	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ER□positive breast cancer. *Exploration of Targeted Anti-tumor Therapy*, **2020**, 1, 355-371	2.5	2
84	Hormone Receptors in Breast Cancer. *Encyclopedia of Pathology*, **2020**, 161-165	0	
83	Breast Pathology. *Encyclopedia of Pathology*, **2020**, 263-268	0	
82	The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting. *Pathobiology*, **2020**, 87, 61-74	3.6	12
81	Metastatic "Ductal Carcinoma In Situ-Like" Lobular Carcinoma in a Lymph Node: A Case Report and Review of the Literature. *International Journal of Surgical Pathology*, **2020**, 28, 436-439	1.2	
80	Radiation-Associated Primary Osteosarcoma of the Breast. *Pathobiology*, **2020**, 87, 322-326	3.6	0
79	Unusual Presentation of Mammary Calciphylaxis in a Patient on Long-Standing Renal Dialysis. *Pathobiology*, **2020**, 87, 317-321	3.6	2
78	Raman spectroscopy of breast cancer. *Applied Spectroscopy Reviews*, **2020**, 55, 439-475	4.5	13
77	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. *Modern Pathology*, **2020**, 33, 354-366	9.8	17
76	Management of B3 Lesions□Practical Issues. *Current Breast Cancer Reports*, **2019**, 11, 83-88	0.8	8
75	Pathology of the male breast. *Diagnostic Histopathology*, **2019**, 25, 138-142	0.7	3

74	Rare morphological appearance of breast carcinoma. *Journal of Clinical Pathology*, **2019**, 72, 90	3.9	1
73	Extramedullary Haematopoiesis in Axillary Lymph Nodes of Breast Carcinoma Patients Receiving Neoadjuvant Chemotherapy: A Potential Diagnostic Pitfall. *Pathobiology*, **2019**, 86, 167-172	3.6	6
72	In situ lobular proliferations of the breast. *Diagnostic Histopathology*, **2018**, 24, 58-63	0.7	2
71	Pathology of High-Risk Breast Lesions **2018**, 103-114		
70	Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. *Breast*, **2018**, 38, 120-124	3.6	11
69	Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. *Journal of Pathology: Clinical Research*, **2018**, 4, 241-249	5.3	10
68	Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India. *Precision Clinical Medicine*, **2018**, 1, 75-87	6.7	3
67	Bilateral Neurofibromas of the Nipple-Areolar Complex: A Case Report and Approach to Diagnosis. *Case Reports in Pathology*, **2018**, 2018, 6702561	0.9	1
66	Metaplastic Breast Cancer Masquerading as Liposarcoma of the Breast: A Case Report following Oncoplastic Treatment. *Pathobiology*, **2018**, 85, 261-265	3.6	0
65	Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities. *Pathobiology*, **2018**, 85, 220-226	3.6	15
64	Remote Teaching of Histopathology Using Scanned Slides via Skype Between the United Kingdom and Nigeria. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 298-300	5	14
63	A rare and unusual cause of mammographic calcification in the breast. *Journal of Clinical Pathology*, **2017**, 70, 89	3.9	0
62	Male Breast Lesions **2017**, 265-274		
61	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. *Scientific Reports*, **2017**, 7, 45293	4.9	29
60	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. *Journal of Cellular Physiology*, **2017**, 232, 2246-2252	7	9
59	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. *Clinical Cancer Research*, **2017**, 23, 2575-2583	12.9	10
58	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. *Scientific Reports*, **2017**, 7, 8078	4.9	13
57	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. *Breast Cancer Research and Treatment*, **2017**, 166, 527-539	4.4	19

56	PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. *Cell Reports*, **2017**, 21, 3498-3513	10.6	81
55	Lobular Neoplasia **2017**, 77-86		
54	Breast Cancer in Sub-Saharan Africa **2017**, 81-93		
53	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. *Scientific Reports*, **2016**, 6, 35121	4.9	5
52	Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. *British Journal of Radiology*, **2016**, 89, 20140644	3.4	14
51	Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype. *Pathobiology*, **2016**, 83, 24-32	3.6	15
50	The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. *Oncotarget*, **2016**, 7, 47927-47937	3.3	16
49	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. *Oncotarget*, **2016**, 7, 43188-43198	3.3	26
48	Breast Cancer Reporting in Lagos, Nigeria: Implications for Training and Education in Africa. *Journal of Global Oncology*, **2016**, 2, 397-402	2.6	11
47	Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. *European Journal of Cancer*, **2016**, 60, 40-8	7.5	36
46	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. *Histopathology*, **2015**, 67, 279-93	7.3	21
45	Prognostic significance of tumour stroma ratio in inflammatory breast cancer. *SpringerPlus*, **2015**, 4, 68		15
44	Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review. *Pathobiology*, **2015**, 82, 124-32	3.6	9
43	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. *Pathobiology*, **2015**, 82, 172-8	3.6	2
42	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. *Breast Cancer Research and Treatment*, **2014**, 148, 73-80	4.4	22
41	Intraductal papilloma in an axillary lymph node of a patient with human immunodeficiency virus: a case report and review of the literature. *Journal of Medical Case Reports*, **2014**, 8, 162	1.2	3
40	Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up. *Clinical Breast Cancer*, **2013**, 13, 486-91	3	8
39	An unusual case of a large fibroepithelial stromal polyp presenting as a nipple mass. *BMC Research Notes*, **2013**, 6, 345	2.3	9

38	Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. *Histopathology*, **2013**, 62, 894-8	7.3	37
37	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. *Breast*, **2013**, 22, 13-8	3.6	34
36	The practicalities of using tissue slices as preclinical organotypic breast cancer models. *Journal of Clinical Pathology*, **2013**, 66, 253-5	3.9	43
35	The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. *Journal of Clinical Pathology*, **2013**, 66, 169-77	3.9	34
34	Pleomorphic lobular carcinoma in situ. *Diagnostic Histopathology*, **2012**, 18, 119-123	0.7	7
33	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. *Breast Cancer Research and Treatment*, **2012**, 133, 949-58	4.4	97
32	Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. *Journal of Clinical Pathology*, **2012**, 65, 403-8	3.9	24
31	Tailoring therapy for locally advanced breast cancer using molecular profiles: are we there yet?. *Drugs*, **2011**, 71, 1947-55	12.1	0
30	Overview of gynecomastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. *Breast Journal*, **2011**, 17, 246-55	1.2	39
29	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. *Breast Cancer Research and Treatment*, **2011**, 127, 639-48	4.4	27
28	Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma. *Hormone Molecular Biology and Clinical Investigation*, **2011**, 7, 273-8	1.3	2
27	What is the significance of flat epithelial atypia and what are the management implications?. *Journal of Clinical Pathology*, **2011**, 64, 1001-4	3.9	9
26	Screen-detected pleomorphic lobular carcinoma in situ (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. *Histopathology*, **2010**, 57, 472-8	7.3	50
25	Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. *Cancer Research*, **2010**, 70, 4778-84	10.1	89
24	Problems (and solutions) in the study of male breast cancer. *Rare Tumors*, **2010**, 2, e28	1.1	5
23	Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. *American Journal of Pathology*, **2010**, 177, 1079-86	5.8	31
22	Differential regulation of oestrogen receptor isoforms by 5Puntranslated regions in cancer. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 2172-84	5.6	25
21	Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. *Breast Cancer Research and Treatment*, **2010**, 121, 555-63	4.4	52

20	Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. *Surgical Oncology*, **2010**, 19, 11-6	2.5	22
19	The rising incidence of male breast cancer. *Breast Cancer Research and Treatment*, **2009**, 115, 429-30	4.4	107
18	Role of ERβ in Clinical Breast Cancer. *Cancer Treatment and Research*, **2009**, 147, 1-20	3.5	
17	Gene Expression of ERβ Isoforms in Laser Microdissected Human Breast Cancers: Implications for Gene Expression Analyses. *Analytical Cellular Pathology*, **2009**, 31, 467-473	3.4	
16	Clinical importance of estrogen receptor beta isoforms in breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 5825; author reply 5825-6	2.2	7
15	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. *Clinical Cancer Research*, **2008**, 14, 5228-35	12.9	187
14	Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. *Clinical Cancer Research*, **2008**, 14, 405-11	12.9	42
13	Hormone receptors in defining breast cancer prognosis--time for a rethink?. *Nature Clinical Practice Oncology*, **2007**, 4, 204-5		4
12	Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. *European Journal of Cancer*, **2007**, 43, 2011-8	7.5	13
11	Estrogen receptor beta--which one and where should we draw the line?. *Human Pathology*, **2006**, 37, 498; author reply 499-500	3.7	1
10	Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. *American Journal of Surgical Pathology*, **2005**, 29, 1593-9	6.7	33
9	A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. *Breast Cancer Research and Treatment*, **2005**, 92, 287-93	4.4	42
8	The estrogen receptors alpha, beta, and beta cx. *Clinical Cancer Research*, **2005**, 11, 8222; author reply 8222-3	12.9	3
7	Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. *Gynecologic Oncology*, **2004**, 92, 628-34	4.9	15
6	Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. *American Journal of Surgical Pathology*, **2003**, 27, 1502-12	6.7	150
5	Re: Skliris et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002; 196: 155-162. *Journal of Pathology*, **2003**, 199, 130; author reply 131	9.4	5
4	Risk for Subsequent Development of Breast Cancer. *American Journal of Surgical Pathology*, **2003**, 27, 271-274	6.7	10
3	Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. *American Journal of Pathology*, **2002**, 160, 597-604	5.8	106

2	Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ		1
1	Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. *Pathobiology*,1-12	3.6	2